Public annual accounts

Axil Bio financials

Name: Axil Bio financials
Creator: Upswitch
License: https://www.upswitch.app/terms-and-conditions

A multi-period view of the public annual-account figures reported for Axil Bio, with comparable measures and links to available source documents.

Company overview

Registry number

0698854118

Fiscal coverage

2024–2025

Public sources

cbso_bulk

Data updated

Jul 28, 2026

Financial evidence

Latest movements for Axil Bio

2025 versus 2024

Operating line: €21,348
EBITDA: €90,564
Total assets: €176,882
Equity: €139,580

EBITDA margin +424.2% · Equity ratio +78.9%

Multi-year filings

Filed annual accounts by fiscal year

Public regulator-filed figures across 2 years.

Source: NBB/CBSO

Fiscal year	Gross margin	EBITDA	Total assets	Equity	Filing
202531 Dec 2025	€21,348	€90,564	€176,882	€139,580	-
202431 Dec 2024	€28,058	€13,498	€233,275	€131,977	-

Gross margin line from gross margin (abbreviated schema). This is not reported turnover, so it is not used as a public valuation base.EBITDA basis: operating profit plus full add-backs.

Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.

Public company datasets

Explore the underlying reports

Valuation

2 valuation checkpoints · 2024 to 2025 · Method family

Open report